KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Revenue: 2010-2024

Historic Revenue for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $661.8 million.

  • Supernus Pharmaceuticals' Revenue rose 9.34% to $192.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $681.5 million, marking a year-over-year increase of 4.54%. This contributed to the annual value of $661.8 million for FY2024, which is 8.94% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Revenue stood at $661.8 million for FY2024, which was up 8.94% from $607.5 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Revenue high stood at $667.2 million for FY2022, and its period low was $520.4 million during FY2020.
  • Moreover, its 3-year median value for Revenue was $661.8 million (2024), whereas its average is $645.5 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Revenue soared by 32.50% in 2020, and later decreased by 8.95% in 2023.
  • Supernus Pharmaceuticals' Revenue (Yearly) stood at $520.4 million in 2020, then rose by 11.41% to $579.8 million in 2021, then climbed by 15.09% to $667.2 million in 2022, then fell by 8.95% to $607.5 million in 2023, then increased by 8.94% to $661.8 million in 2024.